Abstract
Background
Granulocyte colony-stimulating factor (G-CSF) plus plerixafor has been shown to improve
the efficacy of peripheral blood stem cell (PBSC) mobilization, however, due to its
high price, the use of plerixafor is limited in China. The purpose of this study was
to assess the efficacy of residual plerixafor for second-day stem cell mobilization
in multiple myeloma (MM) patients.
Materials and methods
In this single-center retrospective study, 69 MM patients received G-CSF + plerixafor
to mobilize PBSCs, which were collected from 28 patients only for one day and 41 patients
for two days. Some of the patients received residual plerixafor, and PBSCs were collected
on the second day. The data on the characteristics, different doses of plerixafor
and efficacy of PBSC mobilization were collected and analyzed.
Results
After 1 or 2 apheresis procedures, 85.5% of patients collected more than 2 × 106 cells/kg PBSCs. There was no statistically significant difference in the success
rate of CD34 + PBSC mobilization with the different doses of plerixafor on the first
day, but the higher residual plerixafor dose resulted in better success rates on the
second day (P＜0.001). Among the patients who collected PBSCs for two days, the level
of the CD34 + cell yield of 24 patients (58.5%) changed better, which was significantly
correlated with the dose of residual plerixafor on the second day (P = 0.001).
Discussion
These results suggested that the administration of residual plerixafor to mobilize
stem cells on the second day is an economical, efficient and clinically feasible method.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Is there still a role for stem cell transplantation in multiple myeloma.Cancer. 2019; 125: 2534-2543https://doi.org/10.1002/cncr.32060
- Current status of autologous stem cell transplantation for multiple myeloma.Blood Cancer J. 2019; 9: 44https://doi.org/10.1038/s41408-019-0205-9
- Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document.Bone Marrow Transpl. 2020; 55: 811-817https://doi.org/10.1038/s41409-019-0716-9
- Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.Int J Hematol. 2017; 106: 562-572https://doi.org/10.1007/s12185-017-2255-8
- Meloxicam with filgrastim may reduce oxidative stress in hematopoietic progenitor cells during mobilization of autologous peripheral blood stem cells in patients with multiple myeloma.Stem Cell Rev Rep. 2021; 17: 2124-2138https://doi.org/10.1007/s12015-021-10259-y
- Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.Haematologica. 2013; 98: 172-178https://doi.org/10.3324/haematol.2012.071456
- Physiology and pharmacology of plerixafor.Transfus Med Hemother. 2013; 40: 237-245https://doi.org/10.1159/000354132
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood. 2009; 113: 5720-5726https://doi.org/10.1182/blood-2008-08-174946
Statistics NBo. Resident income and consumption expenditure in 2020. National Bureau of Statistics. 〈http://www.stats.gov.cn/xxgk/sjfb/zxfb2020/202101/t20210118_1812464.html〉; [Accessed 01/08/2021].
- Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Bone Marrow Transpl. 2014; 49: 201-205https://doi.org/10.1038/bmt.2013.175
MOZOBIL-plerixafor injection, solution; 2018. 〈https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003〉.
- Chemical stability of plerixafor after opening of single-use vial.Can J Hosp Pharm. 2017; 70: 270-275https://doi.org/10.4212/cjhp.v70i4.1676
- Physicochemical stability of Mozobil® (plerixafor) solution for injection in glass vials and plastic syringes over a three-month storage period.Pharm Technol Hosp Pharm. 2016; 1https://doi.org/10.1515/pthp-2016-0011
- Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: high effectiveness, low toxicity, and affordable cost.Leuk Res Rep. 2020; 14100227https://doi.org/10.1016/j.lrr.2020.100227
- Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.Ann Pharmacother. 2010; 44: 117-126https://doi.org/10.1345/aph.1M380
- Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Biol Blood Marrow Transpl. 2009; 15: 718-723https://doi.org/10.1016/j.bbmt.2009.02.011
- Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.Leukemia. 2011; 25: 1627-1631https://doi.org/10.1038/leu.2011.131
- Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.Leukemia. 2007; 21: 2035-2042https://doi.org/10.1038/sj.leu.2404801
- A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.Clin Pharmacol Ther. 2005; 77: 427-436https://doi.org/10.1016/j.clpt.2004.12.268
- Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.Transfusion. 2018; 58: 323-329https://doi.org/10.1111/trf.14395
- CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent.Pharm Res. 2020; 159105010https://doi.org/10.1016/j.phrs.2020.105010
- Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.Transfusion. 2019; 59: 3721-3726https://doi.org/10.1111/trf.15547
- Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.Leuk Lymphoma. 2019; 60: 2199-2206https://doi.org/10.1080/10428194.2019.1573367
- Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization.Leukemia. 2013; 27: 1407-1411https://doi.org/10.1038/leu.2012.323
- Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.Biol Blood Marrow Transpl. 2009; 15: 39-46https://doi.org/10.1016/j.bbmt.2008.10.018
- Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +/- plerixafor versus granulocyte colony-stimulating factor +/- plerixafor in the lenalidomide era.Transpl Cell Ther. 2021; 27: 590 e1-590 e8https://doi.org/10.1016/j.jtct.2021.04.016
- A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma.Oncol Lett. 2020; 19: 1051-1059https://doi.org/10.3892/ol.2019.11177
- Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting.Biol Blood Marrow Transpl. 2011; 17: 943-955https://doi.org/10.1016/j.bbmt.2010.10.018
Article info
Publication history
Published online: November 25, 2022
Accepted:
November 24,
2022
Received in revised form:
November 21,
2022
Received:
August 12,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Published by Elsevier Ltd.
